Despite positive average three-year growth, Shanghai OPM Biosciences may be risky to invest at current price due to high P/S ratio and less optimistic growth forecast. This overvaluation might lead to potential disappointment for investors.

Shanghai OPM Biosciences' low ROE may alarm investors. Yet, sharp net income rise, perhaps from management choices or minor payout rate, stands out. High-return reinvestment could be driving its earnings surge.